CoChat

Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy

Open access
von Jonquieres, Georg, Spencer, Ziggy H. T., Rowlands, Benjamin D., Klugmann, Claudia B., Bongers, Andre, Harasta, Anne E., Parley, Kristina E., Cederholm, Jennie, Teahan, Orla, Pickford, Russell, Delerue, Fabien, Ittner, Lars M., Fröhlich, Dominik, McLean, Catriona A., Don, Anthony S., Schneider, Miriam, Housley, Gary D., Rae, Caroline D., Klugmann, Matthias · 2018 · Acta Neuropathologica
Cited by 57

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

N-Acetylaspartate (NAA) is the second most abundant organic metabolite in the brain, but its physiological significance remains enigmatic. Toxic NAA accumulation appears to be the key factor for neurological decline in Canavan disease-a fatal neurometabolic disorder caused by deficiency in the NAA-degrading enzyme aspartoacylase. To date clinical outcome of gene replacement therapy for this spongiform leukodystrophy has not met expectations. To identify the target tissue and cells for maximum anticipated treatment benefit, we employed comprehensive phenotyping of novel mouse models to assess cell type-specific consequences of NAA depletion or elevation. We show that NAA-deficiency causes neurological deficits affecting unconscious defensive reactions aimed at protecting the body from external threat. This finding suggests, while NAA reduction is pivotal to treat Canavan disease, abrogating NAA synthesis should be avoided. At the other end of the spectrum, while predicting pathological severity in Canavan disease mice, increased brain NAA levels are not neurotoxic per se. In fact, in transgenic mice overexpressing the NAA synthesising enzyme Nat8l in neurons, supra-physiological NAA levels were uncoupled from neurological deficits. In contrast, elimination of aspartoacylase expression exclusively in oligodendrocytes elicited Canavan disease like pathology. Although conditional aspartoacylase deletion in oligodendrocytes abolished expression in the entire CNS, the remaining aspartoacylase in peripheral organs was sufficient to lower NAA levels, delay disease onset and ameliorate histopathology. However, comparable endpoints of the conditional and complete aspartoacylase knockout indicate that optimal Canavan disease gene replacement therapies should restore aspartoacylase expression in oligodendrocytes. On the basis of these findings we executed an ASPA gene replacement therapy targeting oligodendrocytes in Canavan disease mice resulting in reversal of pre-existing CNS pathology and lasting neurological benefits. This finding signifies the first successful post-symptomatic treatment of a white matter disorder using an adeno-associated virus vector tailored towards oligodendroglial-restricted transgene expression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00401-017-1784-9

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 57

Metadata

Authors
von Jonquieres, G., Spencer, Z. H. T., Rowlands, B. D., Klugmann, C. B., Bongers, A., Harasta, A. E., Parley, K. E., Cederholm, J., Teahan, O., Pickford, R., Delerue, F., Ittner, L. M., Fröhlich, D., McLean, C. A., Don, A. S., Schneider, M., Housley, G. D., Rae, C. D., & Klugmann, M.
Venue
Acta Neuropathologica
Published
2017-11-07
Volume
135
Issue
1
Pages
95-113
ISSN
  • 0001-6322 (ISSN-L)
  • 1432-0533
OpenAlex
W2767544358
Cited by
57
References
19
FWCI
2.62
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy. https://app.cochat.ai/papers/10.1007/s00401-017-1784-9
The paper
von Jonquieres, G., Spencer, Z. H. T., Rowlands, B. D., Klugmann, C. B., Bongers, A., Harasta, A. E., Parley, K. E., Cederholm, J., Teahan, O., Pickford, R., Delerue, F., Ittner, L. M., Fröhlich, D., McLean, C. A., Don, A. S., Schneider, M., Housley, G. D., Rae, C. D., & Klugmann, M. (2018). Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy. Acta Neuropathologica. https://doi.org/10.1007/s00401-017-1784-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.